Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Corvus Pharmaceuticals stock | $4.49

Learn how to easily invest in Corvus Pharmaceuticals stock.

Corvus Pharmaceuticals Inc is a biotechnology business based in the US. Corvus Pharmaceuticals shares (CRVS) are listed on the NASDAQ and all prices are listed in US Dollars. Corvus Pharmaceuticals employs 42 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Corvus Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRVS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Corvus Pharmaceuticals stock price (NASDAQ: CRVS)

Use our graph to track the performance of CRVS stocks over time.

Corvus Pharmaceuticals shares at a glance

Information last updated 2021-10-23.
Latest market close$4.49
52-week range$1.86 - $9.54
50-day moving average $4.77
200-day moving average $3.08
Wall St. target price$5.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.17

Buy Corvus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Corvus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corvus Pharmaceuticals price performance over time

Historical closes compared with the close of $4.49 from 2021-10-25

1 week (2021-10-20) -5.07%
1 month (2021-09-27) -41.46%
3 months (2021-07-27) 113.81%
6 months (2021-04-27) 58.10%
1 year (2020-10-26) 16.32%
2 years (2019-10-25) 44.37%
3 years (2018-10-26) 7.52
5 years (2016-10-26) 14.08

Corvus Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -30.61%
Return on equity TTM -7.85%
Profit margin 0%
Book value $2.27
Market capitalisation $189.6 million

TTM: trailing 12 months

Shorting Corvus Pharmaceuticals shares

There are currently 3.1 million Corvus Pharmaceuticals shares held short by investors – that's known as Corvus Pharmaceuticals's "short interest". This figure is 318.5% up from 735,620 last month.

There are a few different ways that this level of interest in shorting Corvus Pharmaceuticals shares can be evaluated.

Corvus Pharmaceuticals's "short interest ratio" (SIR)

Corvus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corvus Pharmaceuticals shares currently shorted divided by the average quantity of Corvus Pharmaceuticals shares traded daily (recently around 22.0 million). Corvus Pharmaceuticals's SIR currently stands at 0.14. In other words for every 100,000 Corvus Pharmaceuticals shares traded daily on the market, roughly 140 shares are currently held short.

However Corvus Pharmaceuticals's short interest can also be evaluated against the total number of Corvus Pharmaceuticals shares, or, against the total number of tradable Corvus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corvus Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Corvus Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.1043% of the tradable shares (for every 100,000 tradable Corvus Pharmaceuticals shares, roughly 104 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Corvus Pharmaceuticals.

Find out more about how you can short Corvus Pharmaceuticals stock.

Corvus Pharmaceuticals share dividends

We're not expecting Corvus Pharmaceuticals to pay a dividend over the next 12 months.

Corvus Pharmaceuticals share price volatility

Over the last 12 months, Corvus Pharmaceuticals's shares have ranged in value from as little as $1.86 up to $9.54. A popular way to gauge a stock's volatility is its "beta".

CRVS.US volatility(beta: 1.04)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corvus Pharmaceuticals's is 1.037. This would suggest that Corvus Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Corvus Pharmaceuticals overview

Corvus Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines.

Frequently asked questions

What percentage of Corvus Pharmaceuticals is owned by insiders or institutions?
Currently 3.883% of Corvus Pharmaceuticals shares are held by insiders and 54.249% by institutions.
How many people work for Corvus Pharmaceuticals?
Latest data suggests 42 work at Corvus Pharmaceuticals.
When does the fiscal year end for Corvus Pharmaceuticals?
Corvus Pharmaceuticals's fiscal year ends in December.
Where is Corvus Pharmaceuticals based?
Corvus Pharmaceuticals's address is: 863 Mitten Road, Burlingame, CA, United States, 94010
What is Corvus Pharmaceuticals's ISIN number?
Corvus Pharmaceuticals's international securities identification number is: US2210151005
What is Corvus Pharmaceuticals's CUSIP number?
Corvus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 221015100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site